CRMD

CorMedix Inc.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CorMedix Inc. (CRMD) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B (3.5) B- (2.9) B (3.4) C (2.5) C+ (2.6) B- (3.0)
2026-11-04 B (3.5) C+ (2.8) B (3.3) C (2.3) C+ (2.7) B- (2.9)
2026-10-28 B (3.4) C+ (2.8) B (3.4) B- (2.9) C+ (2.7) B- (3.0)
2026-10-21 B (3.4) C+ (2.8) B (3.4) C+ (2.6) C+ (2.6) B- (3.0)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe